CIA
TEVA icon

Cascade Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Cascade Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-39,455
Closed -$1.31M – 184
2017
Q2 		$1.31M Buy
39,455
+3,085
+8% +$95.5K 1.12% 38
2017
Q1 		$1.17M Buy
36,370
+1,925
+6% +$65.7K 1.02% 48
2016
Q4 		$1.25M Buy
+34,445
New +$1.38M 1.06% 46
2016
Q2 		$1.65M Buy
+32,770
New +$1.74M 1.58% 19

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cascade Investment Advisors's TEVA Position: Q3 2017 in Review

Cascade Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 39,455 shares — an estimated $1.31M sold.

Cascade Investment Advisors first reported a position in TEVA in Q2 2016 and held it in 4 quarters. The position peaked at $1.65M in Q2 2016. 536 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Cascade Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Cascade Investment Advisors sold 39,455 Teva Pharmaceuticals shares in Q3 2017, an estimated $1.31M.
  • Cascade Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Cascade Investment Advisors's Teva Pharmaceuticals position peaked at $1.65M in Q2 2016.
  • 536 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Cascade Investment Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.